#Sweden #Lund #Hansa Biopharma #IDEFIRIX #ASN Kidney Week

Positive Results from Idefirix PAES Study at ASN Kidney Week

At the recent American Society of Nephrology (ASN) Kidney Week in Denver, Hansa Biopharma AB unveiled remarkable findings from its European Post-Authorization Efficacy and Safety (PAES) study involving Idefirix (imlifidase). The session was positioned among the High-Impact Clinical Trials, underlining its significance in the field of nephrology and kidney transplantations.

The abstract resonated within the medical community, given its focus on the performance of Idefirix in highly sensitized patients. This group often faces extreme challenges in securing kidney transplants due to having pre-formed antibodies against many human leukocyte antigens (HLAs). The necessity for research in this area is paramount; approximately 10-15% of transplant waiting lists comprise highly sensitized patients who struggle to find compatible donors.

Hansa's PAES study included 50 patients who received crossmatch positive kidney offers and treated them with imlifidase, enabling a transformation from a positive to a negative crossmatch. This conversion is critical because it opens the door for these patients to receive otherwise incompatible organs.

Study Outcomes

The results are encouraging: the study documented a 90% graft failure-free survival rate at 12 months post-transplant. Specifically, graft survival was reported at 92%, while patient survival reached an impressive 98%. Such statistics not only highlight the efficiency of Idefirix but also its potential to shift the paradigm for highly sensitized transplant candidates.

While the mean estimated Glomerular Filtration Rate (eGFR) was recorded at 51.04 mL/min/1.73 m², the study identified delayed graft function (DGF) in 40% of the subjects, with a median lasting 14 days. Antibody-mediated rejection (AMR) manifested in 56% of the participants; however, it is notable that no allograft was lost due to AMR, showcasing the potential benefits of imlifidase in managing prior immunological complications that could jeopardize transplant success.

Additionally, the safety of Idefirix was found to be in line with previous findings, showing no new safety signals and maintaining a profile that aligns with prior clinical trial experiences.

Expert Commentary

Renée Aguiar-Lucander, Hansa Biopharma's CEO, expressed the significance of these findings, emphasizing their impact on a demographic long overlooked in kidney transplantation discussions. Dr. Oriol Bestard from Vall d'Hebron University Hospital, who also contributed to the study, underscored that successful PAES results promise crucial advances for highly sensitized patients facing unfair challenges in the transplant landscape.

Importance of ASN Kidney Week

The ASN Kidney Week stands as a premier global gathering for nephrology professionals, showcasing the latest scientific discoveries and clinical practices in kidney disease management. This year’s conference was particularly resonant considering the increasing emphasis on understanding kidney diseases and enhancing transplantation outcomes.

Hansa Biopharma’s presentation serves as an important reminder of the critical intersection of clinical innovation and the urgent needs of patients with complex medical profiles. The evidence amassed through the PAES study provides a compelling case for adopting strategies that prioritize desensitization therapies like Idefirix, allowing for a more inclusive transplantation process.

Conclusion

With the groundwork laid by the PAES findings, the potential for imlifidase to revolutionize kidney transplants for highly sensitized patients is evident. It beckons further clinical exploration and partnership discussions, paving the way for improved patient outcomes and possibly reshaping the waiting list narrative in transplantation.

For more details on the ongoing research and outcomes associated with Idefirix, follow updates on ClinicalTrials.gov.